This site is intended for U.S. healthcare professionals.
ELREXFIO is an off-the-shelf BCMA-directed bispecific immunotherapy2
In the single-arm, Phase 2 MagnetisMM-3 study, 57.7% ORR (56/97) and 51.5% ≥VGPR (50/97) were achieved in adult patients with RRMM who had no prior BCMA-directed therapy and had received at least four prior lines of therapy.
To report an adverse event, please call 1-800-438-1985
Pfizer for Professionals 1-800-505-4426
This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.
© 2023 Pfizer Inc. All rights reserved.